

# 2008 Annual General Meeting

JP Garnier
Chief Executive Officer

### **GSK Performance and return to shareholders**



2007 Dividend

53p +10%

Share buy-backs

£12bn over 2 years; £3.5bn completed

## 2008: The year unfolding ...

1st Quarter **Issues** Avandia (£230m\*) **Generics** (£249m\*)

<sup>\*</sup> CER growth. Global Avandia decline; generic decline due to Coreg franchise, Zofran and Flonase (global sales)

### Avandia US market share stabilising


### Recent retail weekly market share



Source: Verispan, VONA

Switch Add-on represents a patient who was already on an OAD, who was either switched to Avandia or had Avandia added to their regimen.

# 2008: The year unfolding ...



<sup>\*</sup> CER growth. Global Avandia decline; generic decline due to Coreg franchise, Zofran and Flonase (global sales)

# Strong pharma performances in first quarter

Advair	£954m	+10%
Vaccines	£436m	+10%
Lamictal	£290m	+16%
Valtrex	£249m	+9%
Requip	£94m	+15%
Avodart	£85m	+30%
Lovaza	£50m	+72%*
Boniva	£49m	+50%
Arixtra	£35m	+70%
Tykerb, Veramyst	£32m	>100%

<sup>\*</sup> Pro forma CER growth

### Advair/Seretide - sales £954 million +10%

#### Reported sales and CER growth rate



### US Vaccine sales £109m +34%

### **Current portfolio**

















New opportunities '08 & '09










H5N1 pandemic

### Strong new addition to US sales portfolio



- Only FDA-approved prescription omega-3 product
- Dramatic reductions in triglycerides in a very natural way
- A product with 'No Warnings'

# Consumer Healthcare continuing strong performance






## R&D: "life blood of the company"



### **Evolution of the GSK R&D model**



### Pipeline is delivering

33 Phase III / Filed#

Phase II

Phase I

Up to 25 potential launches 2007-2009\*

13 NCEs

**5** Vaccines

7 PLEs

<sup>\*</sup> Includes launches which have taken place during 2007 and up to May2008

## Significant number of new product contributions

2007 Key launches













## Significant number of new product contributions

2007 Key launches















Just approved...



For POI



**COPD** exacerbations



(CombAT study)



Treximet *Prepandrix* 



## Significant number of new product contributions

2007 Key launches















Just approved...



For POI



**COPD** exacerbations



(CombAT study)



Treximet Prepandrix



...2008 pending













### **Leading the industry**



### ...with significant "reloadability"



### 2008 Outlook for GSK

GSK: Strong fundamentals

Challenging and fast changing environment

Need to continue to adjust the business model

